Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Male Sexual Response: Erection & Ejaculation01:17

Male Sexual Response: Erection & Ejaculation

Sexual stimulation can take various forms, such as physical touch and visual or auditory cues. When this happens, the parasympathetic reflex in the sacral portion of the spinal cord is activated. This reflex stimulates the release of nitric oxide (NO), which then dilates the arterioles in the penis, increasing blood flow to the erectile tissues - the corpora cavernosa and corpus spongiosum.
The blood filling the erectile tissues compresses the veins, which helps to prevent blood from leaving...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical Timing and Patient Heterogeneity in Interpreting Minimal Important Change After Vertebroplasty for Osteoporotic Vertebral Compression Fractures.

Spine·2026
Same author

Comparative efficacy and safety of unilateral biportal endoscopic posterior cervical foraminotomy versus anterior cervical discectomy and fusion for single-level cervical radiculopathy: a retrospective cohort study.

Journal of spine surgery (Hong Kong)·2026
Same author

Single-cell multi-omic integration analysis prioritizes druggable genes and reveals cell-type-specific causal effects in glioblastomagenesis.

Journal of translational medicine·2026
Same author

Exposure to high ambient temperature during pre-implantation impairs embryo transport and development in the oviduct: Potential association with ANO1 downregulation.

Journal of thermal biology·2026
Same author

Metagenomic analysis of intestinal microbiota characteristic differences between patients with ankylosing spondylitis and healthy individuals.

BMC microbiology·2026
Same author

Metagenomics-based characterization of fecal microbiome and resistome of laying hens during the production cycle.

Frontiers in veterinary science·2026

Related Experiment Video

Updated: Jun 15, 2026

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
04:22

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

[Vardenafil for refractory erectile dysfunction: the latest advances].

Hao-Yang Wang1, Yu-Feng Huang

  • 1Department of Reproduction and Genetics, PLA Research Institute of Clinical Laboratory Medicine, Nanjing General Hospital of Nanjing Military Region, Nanjing, Jiangsu 210002, China.

Zhonghua Nan Ke Xue = National Journal of Andrology
|March 12, 2010
PubMed
Summary

Vardenafil effectively treats erectile dysfunction (ED) by targeting the phosphodiesterase 5 (PDE5) pathway. This medication offers a safe therapeutic option for various ED causes and prolongs erectile duration.

Related Experiment Videos

Last Updated: Jun 15, 2026

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
04:22

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

Area of Science:

  • Urology
  • Pharmacology
  • Physiology

Context:

  • Erectile dysfunction (ED) is linked to the cyclic nucleotide (cGMP) signaling pathway.
  • Down-regulation of this pathway is central to ED pathogenesis and chronic diseases.
  • Nitric oxide's smooth-muscle relaxing effect, crucial for erection, relies on this pathway.

Purpose:

  • To evaluate vardenafil's efficacy and safety in treating diverse forms of ED.
  • To assess vardenafil as a therapeutic alternative for refractory ED patients.
  • To determine vardenafil's impact on erectile duration.

Summary:

  • Vardenafil is effective and safe for ED associated with dyslipidemia, hypertension, depression, diabetes, and post-surgical complications.
  • It addresses ED linked to spinal cord injury, chronic prostatitis, and premature ejaculation.
  • Vardenafil is a viable treatment for patients with prior sildenafil failure and post-renal transplantation.

Impact:

  • Vardenafil offers a new therapeutic avenue for patients with refractory erectile dysfunction.
  • The drug demonstrates potential in managing ED across a wide spectrum of underlying conditions.
  • Clinical outcomes suggest vardenafil can improve erectile function duration.